Thymosin Alpha-1: what the literature examines, and the molecule it gets confused with

Thymosin Alpha-1 is a 28–amino acid peptide, CAS 62304-98-7, originally isolated from thymic tissue — the gland where T-cells are trained during immune development.

It is unusual among research peptides in two ways. The first is that it has a genuine clinical history rather than only preclinical work. The second is that it is routinely mistaken for a molecule it has nothing to do with.

Two peptides, one name

Thymosin Alpha-1 and Thymosin Beta-4 are not variants of each other. They are not related. They were pulled out of the same tissue fraction in the 1960s and 70s and named by which chromatographic fraction they turned up in — alpha, beta — which is a filing convention, not a statement about structure or function.

What they share is a name prefix and an acetylated N-terminus. That is the whole overlap. Choosing between them is not choosing a strength or a grade — it is choosing between two unrelated mechanisms, and a protocol written for one tells you nothing about the other.

What it binds

Thymosin Alpha-1 acts on innate immune signalling rather than on one downstream target. The best-characterised interaction is agonism at Toll-like receptors — TLR2 and TLR9 in particular — on dendritic cells and monocytes. Engaging those receptors changes how dendritic cells mature, and dendritic cell maturation is upstream of how naive T-cells differentiate. So the peptide sits one or two steps back from the endpoints people care about, which is part of why its effects are described as context-dependent.

That context dependence is the recurring theme. The literature does not describe a peptide that pushes immunity up or down. It describes an immune modulator: in models of immune suppression, reported restoration of T-cell responsiveness; in models of excessive inflammation, reported dampening of the response. Bidirectional behaviour of that kind is uncommon, and it is the main reason the molecule has held research interest for four decades.

It is also the reason its trial record is hard to read. A compound whose reported effect depends on the immune state of the system it enters will behave differently across populations, and differences between studies are then difficult to attribute to the compound rather than to the cohort.

How far the evidence goes

Further than for most things in this catalogue — which is a low bar, and worth stating precisely rather than leaving as an impression.

Thymosin Alpha-1 has been examined in human trials, not only in cells and animals. The published work covers chronic hepatitis B and C, sepsis, immune reconstitution during chemotherapy, and use as a vaccine adjuvant in elderly populations, where response to vaccination is blunted. That is a real clinical literature spanning decades.

What it is not is a settled one. The indications above are not equally supported; some are single trials or small cohorts, and the hepatitis work is where the evidence is deepest because that is what the licensed product was registered on. Trials in sepsis and in vaccine response are a research question, not a resolved one. 'Studied in sepsis' means studies exist — it does not mean they agreed.

Regulatory status, stated plainly

Thymosin Alpha-1 is licensed as Zadaxin in roughly 35 countries, for specific indications. It is not approved in Canada and not approved in the United States — not by Health Canada, not by the FDA.

That position gets misread in both directions, so both halves matter. Approval in those 35 jurisdictions means the molecule passed safety and efficacy review there, for named indications, as a manufactured medicine. It does not extend to Canada or the US, it does not cover anything outside those indications, and it does not transfer to material bought from a research supplier. Research-grade Thymosin Alpha-1 is not Zadaxin: it is not prescribed, not dispensed, not supplied against a licence, and is sold for laboratory use only.

Amounts used in the licensed product come from approved-indication protocols in the jurisdictions that licensed it, applied under medical supervision. Those figures are not a template for anything, and they are not reproduced here.

The variable a laboratory actually controls

For bench work the controllable quantity is concentration, which is arithmetic rather than protocol.

A 10 mg vial reconstituted with 2 mL of bacteriostatic water yields 5 mg/mL. The same vial with 5 mL yields 2 mg/mL. Pick the volume that puts the working concentration where the protocol needs it.

Handling. Sealed and lyophilised: 2–8 °C protected from light, −20 °C for long-term storage. Reconstitute with bacteriostatic water, sold separately, added slowly down the vial wall — do not shake. Agitation denatures peptides at the air-liquid interface, and a vial that has been shaken into a foam has lost material you cannot account for. Once reconstituted, keep refrigerated.

Verification. Janoshik-tested batches carry a unique report key that can be checked against the laboratory directly rather than taken from the seller's copy.

Thymosin Alpha-1 is supplied here as Thymosin Alpha-1 10mg. Janoshik-verified by HPLC with mass-spec identity confirmation; 100% synthetic. The measured purity for each lot is stated on its product page. For laboratory research use only.

Common questions

Is Thymosin Alpha-1 the same as TB-500? No, and the confusion is purely historical. TB-500 refers to Thymosin Beta-4, a 43–amino acid peptide examined in tissue repair and angiogenesis through actin binding. Thymosin Alpha-1 is a 28–amino acid immunopeptide examined in T-cell maturation and Toll-like receptor signalling. Two molecules, one naming convention from the era they were separated.

It is approved somewhere — doesn't that make it safe? It makes the licensed product, manufactured to a pharmacopoeial standard and given under supervision for a named indication, something a regulator in those countries accepted. None of that attaches to research-grade material in a jurisdiction where the drug has no licence. The approval is for a specific product, a specific indication and a specific chain of custody, and research material has none of the three.

Why is the mechanism described so vaguely? Because it acts through receptors that sit upstream of immune cell differentiation rather than on a single effector. Receptor-level agonism at TLR2 and TLR9 is characterised; what that produces depends on the immune state of the system. A description that sounded more definite would be less accurate.

Is it legal to buy in Canada? It is sold here as a research chemical for laboratory use only. It is not an approved drug in Canada, and it is not sold for human use.

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.